<DOC>
	<DOCNO>NCT00992290</DOCNO>
	<brief_summary>This research propose find whether probiotic lactobacillus GG safe well tolerated patient minimal hepatic encephalopathy . We also want get insight mechanism action LGG .</brief_summary>
	<brief_title>Probiotic Lactobacillus GG ( LGG ) Patients With Minimal Hepatic Encephalopathy</brief_title>
	<detailed_description>Development complementary alternative medicine approach liver disease priority area NCCAM . Minimal hepatic encephalopathy ( MHE ) significant complication cirrhosis result poor quality life , impaired cognition difficulty drive motor vehicle high traffic accident risk . MHE estimate affect one half 5.5 million cirrhotics U.S . Despite negative outcome , consensus treatment MHE . Currently available therapy MHE act intestinal flora limited adverse effect ( i.e . lactulose-induced diarrhea ) , negatively impact adherence . Probiotic bacterial supplement , also act intestinal flora , emerge therapy MHE . Our group perform pilot , randomize trial demonstrate significantly high rate MHE reversal excellent adherence patient randomize probiotic yogurt compare therapy . This proposal intend define Lactobacillus GG ( LGG ) biologically-based alternative therapy MHE special focus metabolic stool bacteriologic change . The hypothesis Phase I proposal : LGG safe efficacious treatment minimal hepatic encephalopathy compare placebo randomize , double-blind trial . This carry four specific aim : Specific aim 1 : To define safety tolerability LGG patient minimal hepatic encephalopathy placebo Phase I randomize control trial . Specific aim 2 : To define effect LGG intestinal microflora composition cirrhotics minimal hepatic encephalopathy use 16 stool DNA sequence randomize , placebo-controlled trial . Specific aim 3 : To determine effect LGG metabolic biomarkers cytokines stool , urine blood use nuclear magnetic resonance spectroscopy minimal hepatic encephalopathy . Specific aim 4 : To determine effect LGG psychometric function patient minimal hepatic encephalopathy . The specific aim sub-aims test 30 patient non-alcoholic cirrhosis MHE : 15 randomize LGG 15 randomize placebo take BID 8 week detailed psychometric , metabolic , anthropometric bacteriologic evaluation . Results generate study form basis RO1 proposal develop use probiotic biologically-based alternative treatment long-term outcome prognosis , development overt encephalopathy prevention traffic accident patient MHE .</detailed_description>
	<mesh_term>Brain Diseases</mesh_term>
	<mesh_term>Hepatic Encephalopathy</mesh_term>
	<criteria>Age : 1865 year Histological evidence cirrhosis Maintenance cirrhosis treatment stability 6 month Minimental state exam score &gt; 25 Presence MHE psychometric test Rx MHE OHE Antibiotics within 6 week Yogurt consumption within 2 week Neutrophil count &lt; 500 Inflammatory bowel disease History pancreatitis Hepatocellular carcinoma Recent ( 6 week ) gastrointestinal bleed Recent ( 6 month ) alcohol intake Psychoactive medication ( include interferon/antipsychotics ) Liver transplant</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>January 2014</verification_date>
	<keyword>cirrhosis</keyword>
	<keyword>hepatic encephalopathy</keyword>
	<keyword>complication</keyword>
	<keyword>probiotic</keyword>
	<keyword>lactobacillus GG</keyword>
</DOC>